Payment overview · 2025
General Payments
$141.91
6 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher John O'Grady, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · WATSONVILLE, CA · NPI 1861474306
Verified facts
What the public records show
CMS Open Payments records show Christopher John O'Grady, M.D. received $141.91 in general payments during 2025 across 6 reported records.
Dexcom, Inc. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $55.01 | 38.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.70 | 35.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.20 | 12.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.00 | 12.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.91 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $55.01 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
101 | 101 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
39 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 74 |
| Losartan Potassium | Losartan Potassium | 250 | 65 |
| Omeprazole | Omeprazole | 247 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 47 |
| Gabapentin | Gabapentin | 203 | 57 |
| Metformin Hcl | Metformin Hcl | 201 | 48 |
| Lisinopril | Lisinopril | 185 | 41 |
| Potassium Chloride | Potassium Chloride | 177 | 38 |
| Simvastatin | Simvastatin | 170 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 29 |
| Furosemide | Furosemide | 125 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 36 |
| Lorazepam | Lorazepam | 117 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 26 |
| Alprazolam | Alprazolam | 114 | 32 |
| Eliquis | Apixaban | 112 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 37 |
| Prednisone | Prednisone | 110 | 43 |
| Allopurinol | Allopurinol | 108 | 25 |
| Alendronate Sodium | Alendronate Sodium | 107 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 29 |
| Famotidine | Famotidine | 105 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 101 | 101 |
| Finasteride | Finasteride | 98 | 24 |
| Trazodone Hcl | Trazodone Hcl | 94 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 19 |
| Atenolol | Atenolol | 89 | 20 |
| Celecoxib | Celecoxib | 89 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 22 |
| Clonazepam | Clonazepam | 84 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 25 |
| Pregabalin | Pregabalin | 77 | 16 |
| Jardiance | Empagliflozin | 72 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 16 |
| Cephalexin | Cephalexin | 66 | 48 |
| Ozempic | Semaglutide | 66 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 22 |
| Tramadol Hcl | Tramadol Hcl | 63 | 14 |
| Mirtazapine | Mirtazapine | 61 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 11 |
| Meloxicam | Meloxicam | 60 | 19 |
| Montelukast Sodium | Montelukast Sodium | 60 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | suppressed |
| Temazepam | Temazepam | 58 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | suppressed |
| Trulicity | Dulaglutide | 55 | suppressed |
| Azithromycin | Azithromycin | 52 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 14 |
| Linzess | Linaclotide | 48 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Hydrocortisone | Hydrocortisone | 44 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 16 |
| Valacyclovir | Valacyclovir Hcl | 44 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Glipizide | Glipizide | 41 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 31 |
| Torsemide | Torsemide | 39 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 30 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Valsartan | Valsartan | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Nystatin | Nystatin | 32 | 18 |
| Premarin | Estrogens, Conjugated | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 23 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Minoxidil | Minoxidil | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | 14 |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Alprazolam Er | Alprazolam | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Naproxen | Naproxen | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Arthrotec 75 | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Riluzole | Riluzole | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.91 · 6 records | Dexcom, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, NURTEC ODT, TRELEGY ELLIPTA, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error